Wutah pendapatan taun lumaku: Cellectar Corp (CLRB)

Logo perusahaan publik cellectar.com (CLRB)

Amidst fierce competition for radiopharmaceutical patents, the rolling annual revenue growth rate helps assess business dynamics. The current value of this metric is 0.00. Cellectar Biosciences (CLRB) maintains a competitive edge through its unique PDC platform for targeted drug delivery, which reduces toxicity. The company is currently scaling its drug portfolio and finalizing tests for its lead candidate prior to market launch.

Cellectar Biosciences (CLRB): Wutah pendapatan YoY sajrone 12 wulan kepungkur saka 11.02.2024 nganti 16.11.2026

Cellectar Biosciences - rincian analitis lan metrik utama (CLRB)

- rega saham lan target rega konsensus:
- indikator kapitalisasi bursa perusahaan:
Ringkesan analitik perusahaan:Cellectar
Produk merek Cellectar Corp

Developing radiopharmaceuticals for oncology requires an assessment of incoming cash flow stability. The calculation algorithm aggregates revenue over twelve months, excluding one-time accounting adjustments to identify the net trend. This metric measures real revenue dynamics, neutralizing distortions caused by the low-base effect. The diversification of the Cellectar Biosciences (CLRB) clinical pipeline makes this indicator a key marker of commercial viability. By analyzing this TTM year-over-year sales growth rate chart, an investor determines the structural resilience of the business.

Karo sapa Cellectar Biosciences saingan

Incyte Pharma - Wutah dodolan YoY sajrone rolas wulan kepungkur|HUTCHMED Corp - Wutah dodolan YoY (TTM)|Wutah pendapatan taun lumaku Nuvation Bio Inc.|DAWN: Wutah dodolan YoY (TTM)|Tingkat wutah pendapatan YoY sajrone rolas wulan kepungkur Monopar Pharma MNPR|Wutah pendapatan YoY sajrone 12 wulan kepungkur INBX|Wutah pendapatan taun lumaku I-Mab Biopharma IMAB|Wutah pendapatan YoY sajrone 12 wulan kepungkur FENC (Fennec Pharmaceuticals)|HRTX (Heron Therapeutics Inc) - Dinamika pendapatan YoY sajrone rolas wulan kepungkur|Nuvectis Pharma, Inc. - Wutah pendapatan YoY sajrone 12 wulan kepungkur|Owah-owahan pendapatan YoY sajrone 12 wulan kepungkur CHRS (Coherus BioSciences)|Corbus Pharma - Wutah dodolan YoY (TTM)|Dinamika pendapatan YoY sajrone rolas wulan kepungkur CRDF (cardiffoncology.com)|BYSI: Wutah dodolan YoY (TTM)|Wutah pendapatan taun lumaku BioAtla Corp (BCAB)|Wutah dodolan YoY sajrone rolas wulan kepungkur Lixte Biotechnology Holdings, Inc.|CTXR: Dinamika pendapatan YoY sajrone rolas wulan kepungkur|Wutah dodolan YoY (TTM) BLRX|Wutah dodolan YoY (TTM) Can-Fite (CANF)|Wutah dodolan YoY sajrone rolas wulan kepungkur Aprea Therapeutics Inc. APRE|KZIA (kaziatherapeutics.com) - Wutah dodolan taun lumaku|SLXN: Wutah pendapatan YoY sajrone 12 wulan kepungkur|Wutah pendapatan taun lumaku NuCana|CMRX: Wutah dodolan YoY (TTM)|Wutah pendapatan YoY sajrone 12 wulan kepungkur Cyclacel Pharmaceuticals|GTHX (g1therapeutics.com) - Wutah dodolan YoY (TTM)|KRON: Dinamika pendapatan YoY sajrone rolas wulan kepungkur|Wutah dodolan YoY sajrone rolas wulan kepungkur Kintara (KTRA)|Wutah pendapatan YoY sajrone 12 wulan kepungkur Oncternal ONCT|Portage Biotech - Wutah pendapatan YoY sajrone 12 wulan kepungkur